Bordetella pertussis Isolates with a Heterogeneous Phenotype for Erythromycin Resistance
AUTOR(ES)
Wilson, K. E.
FONTE
American Society for Microbiology
RESUMO
Erythromycin is currently being used for both prophylaxis and treatment of pertussis infections. Erythromycin resistance was first recognized in Bordetella pertussis in Arizona in 1994, and since then, three additional resistant isolates have been identified in the United States. To better assess the potential public health impact of erythromycin-resistant B. pertussis, we used the disk diffusion assay to evaluate the frequency of erythromycin resistance among 1,030 recently circulating U.S. isolates and found the rate of occurrence to be <1%. We also describe a novel heterogeneous phenotype, with erythromycin-resistant colonies appearing only after a 7-day incubation period. To optimize patient management, we recommend that clinicians be alert to potential treatment failures and that laboratorians use a 7-day incubation period when screening for resistance. Our ongoing national surveillance will continue to monitor for resistant B. pertussis isolates and their potential association with changing pertussis epidemiology.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=120648Documentos Relacionados
- Identification of a Mutation Associated with Erythromycin Resistance in Bordetella pertussis: Implications for Surveillance of Antimicrobial Resistance
- A Simplified Method for Testing Bordetella pertussis for Resistance to Erythromycin and Other Antimicrobial Agents
- Surveillance and detection of erythromycin resistance in Bordetella pertussis isolates recovered from a pediatric population in the Intermountain West region of the United States.
- Inducible Azole Resistance Associated with a Heterogeneous Phenotype in Candida albicans
- Fimbrial Typing of Bordetella pertussis Isolates: Agglutination with Polyclonal and Monoclonal Antisera
